Importantly, neutralizing antibodies against WISP1 attenuated the development of bleomycin-induced pulmonary fibrosis in vivo, thus demonstrating the potential of WISP1 as a therapeutic target for IPF13. Here, CCN4 is linked to pulmonary fibrosis.